A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

Summary

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.

Eligibility

Inclusion Criteria:

* Participants must be ≥ 18 years of age at the time of signing the ICF.
* Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World

Health Organization or local diagnostic standards, inadequately managed with:

1. Lifestyle management alone, AND/OR
2. A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF.

   * Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required.
   * Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis.

Exclusion Criteria:

* Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol).
* Diagnosed with Type 1 diabetes mellitus.
* Known pregnancy at the time of visit or having the intention to become pregnant.

Conditions2

Locations6 sites

Find trials near these locations

Browse More Trials